SCHEMBL17847842

SCHEMBL17847842

COc1ccc2c(c1)C(CC(=O)N(C)CCN(C)C)=C(C)C2=Cc1ccc(N(C)C)cc1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RXRA P19793 5/20 0.46
PPARG P37231 5/20 0.45
MAOB P27338 4/20 0.43
MAOA P21397 2/20 0.43
MAPT P10636 6/20 0.39
MAPK1 P28482 4/20 0.39
KMT2A Q03164 3/20 0.39
MEN1 O00255 2/20 0.39
USP2 O75604 1/20 0.39
TLR9 Q9NR96 1/20 0.39
L3MBTL1 Q9Y468 1/20 0.39
CYP1A2 P05177 3/20 0.38
PTGS2 P35354 2/20 0.38
TDP1 Q9NUW8 2/20 0.38
EGFR P00533 1/20 0.38
ADORA3 P0DMS8 1/20 0.38
DRD1 P21728 1/20 0.38
PTGS1 P23219 1/20 0.38
OPRM1 P35372 1/20 0.38
PSEN1 P49768 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17847838 1.00 RXRA (0.46) RXRAPPARGMAOBMAOAMAPT
SCHEMBL19862423 0.89 PPARG (0.49) RXRAPPARGMAPTMAPK1KMT2A
SCHEMBL17854911 0.89 PPARG (0.52) RXRAPPARGMAOBMAPTMAPK1
SCHEMBL24740945 0.87 RXRA (0.44) RXRAPPARGMAOBMAPTMAPK1
SCHEMBL19862422 0.86 PPARG (0.60) RXRAPPARGMAOBMAOAMAPT
SCHEMBL21805849 0.86 PPARG (0.60) RXRAPPARGMAOBMAOAMAPT
SCHEMBL17854899 0.82 PPARG (0.44) RXRAPPARG
SCHEMBL21376111 0.79 PPARG (0.50) RXRAPPARGMAPTMAPK1KMT2A
SCHEMBL8432124 0.77 MAOB (0.45) RXRAPPARGMAOBMAOAMAPT
SCHEMBL8681652 0.74 PPARG (0.64) RXRAPPARGMAPTMAPK1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12479813-B2 Method of therapeutically treating cancer ADT PHARMACEUTICALS, LLC (US) 2025-11-25 US claimed
US-20220315553-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, LLC (US) 2022-10-06 US claimed
EP-3233794-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT Pharmaceuticals, Inc. (US) 2017-10-25 EP claimed
WO-2016100542-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, INC. (US) 2016-06-23 WO claimed
US-12479813-B2 Method of therapeutically treating cancer ADT PHARMACEUTICALS, LLC (US) 2025-11-25 US disclosed
EP-3233794-B1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS AND MEDICAL USES THEREOF ADT PHARMACEUTICALS LLC (US) 2023-02-01 EP disclosed
US-20220315553-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, LLC (US) 2022-10-06 US disclosed
EP-4053105-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT Pharmaceuticals, LLC (US) 2022-09-07 EP disclosed
US-11407727-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof ADT PHARMACEUTICALS, LLC (US) 2022-08-09 US disclosed
US-11130744-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof ADT PHARMACEUTICALS, LLC (US) 2021-09-28 US disclosed
US-10981886-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof ADT PHARMACEUTICALS, LLC (US) 2021-04-20 US disclosed
US-10975054-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof ADT PHARMACEUTICALS, LLC (US) 2021-04-13 US disclosed
CN-107531615-B Indenyl compound, pharmaceutical composition and medical application thereof ADT制药有限责任公司 2020-09-04 CN disclosed
US-20200223815-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, LLC (US) 2020-07-16 US disclosed
US-20200223816-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, LLC (US) 2020-07-16 US disclosed
US-20200048217-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, LLC (US) 2020-02-13 US disclosed
US-20200031795-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, LLC (US) 2020-01-30 US disclosed
US-20180208573-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF BOYD, MICHAEL R. 2018-07-26 US disclosed
EP-3233794-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT Pharmaceuticals, Inc. (US) 2017-10-25 EP disclosed
WO-2016100542-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF ADT PHARMACEUTICALS, INC. (US) 2016-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (11 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315553-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-20200223815-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-20200031795-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-20200048217-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-12479813-B2 Method of therapeutically treating cancer RECQL, RDX, RNASE1 RXRA 40/4885PPARG 1690/4885MAOB 1796/4885
US-20180208573-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF INSRR, INSR, BRCA1 RXRA 156/4885PPARG 2746/4885MAOB 1037/4885
US-11407727-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-11130744-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-10981886-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-20200223816-A1 INDENYL COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND MEDICAL USES THEREOF INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885
US-10975054-B2 Indenyl compounds, pharmaceutical compositions, and medical uses thereof INSRR, INSR, BRCA1 RXRA 124/4885PPARG 2965/4885MAOB 1257/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.